MiNK Therapeutics reported second quarter 2026 financial results and provided an update on its randomized Phase 2 study of agenT-797 in acute lung injury and ARDS. The company ended the quarter with $8.8 million in cash and cash equivalents, compared with $9.5 million at March 31, 2026, and $3.4 million at year-end 2025. Net loss narrowed to $3.1 million, or $0.62 per share, from $4.2 million, or $1.06 per share, in the prior year period. The company initiated dosing in Ukraine and expects U.S. sites to begin enrollment in September 2026, with additional data expected in early 2027. MiNK also launched a paid named-patient access program in Brazil and is preparing for an FDA meeting to discuss a seamless Phase 3 study.
Mink Therapeutics IncQ2 results show narrowed net loss and cash position, with progress in Phase 2 study and upcoming FDA meeting.
